lURIE CANCER CENTER AND Northwestern Medicine
EXPERTS TO PRESENT AT THE 2024 ASTRO Annual Meeting
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss on top-tier science and education in radiation oncology at the 66th ASTRO Annual Meeting in Washington, DC, from September 29 to October 2, 2024.
a sample of our presentation schedule
|
Presenter
|
Date & Time
|
Track & Session
|
|
Sunday, September 29, 2024
2:45 - 4:00 pm |
Session Title: GYN 3: Quest for Prognostic and Predictive Biomarkers in Gynecological Malignancies
|
|
|
|
Sunday, September 29, 2024
2:00 - 3:00 pm |
Accuray Symposium: Innovative Radiotherapeutic Techniques for Multiple Brain Metastases
|
|
|
TBD
|
Moderator to Session: Envisioning the Future: Leading Edge Research in HPV-Associated Oropharyngeal Cancer
|
|
TBD
|
Presentation: Results of a Dose Reconstruction Effort for a Large-Scale Retrospective Study on Late Health Effects Following Radiotherapy within the National Wilms Tumor Study
|
|
connect with us on social
Use #ASTRO24 to follow and share insights from the meeting on Twitter, tagging:
- Lurie Cancer Center: @LurieCancer
- Northwestern Medicine: @NorthwesternMed
NORTHWESTERN MEDICINE onCOLOGY
|
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a global leader in the treatment of a broad range of cancer types due to its dedication to comprehensive clinical oncology research, world-renowned faculty, physicians and oncologists, and its commitment to making breakthroughs in medical, surgical, radiation and interventional oncology. The Lurie Cancer Center is designated by the National Cancer Institute as one of only 57 comprehensive cancer centers in the nation recognized for their scientific leadership, resources and the depth and breadth of their research. In addition, Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN) and our physicians actively participate in writing NCCN patient guidelines for each type cancer.
|